Origin Genomics Founder Argues Gene-Editing Embryos Is a Moral Imperative
Cathy Tie, founder of Origin Genomics, argues that editing human embryos to prevent hereditary diseases is a moral imperative, despite current U.S. bans and safety concerns. While critics warn of eugenics and off-target risks, proponents cite new precise editing tools and patient demand for alternatives to IVF screening.
Key points
- Cathy Tie, 30, launched Origin Genomics in March 2026 to develop gene-edited embryos for IVF clinics, arguing it is a 'moral imperative' to prevent hereditary diseases.
- Tie published a commentary in Trends in Genetics calling for public funding and regulatory changes to allow clinical use, despite current U.S. laws barring FDA trials on heritable embryo modifications.
- Critics, including Stanford law professor Hank Greely, warn that off-target effects could introduce new health risks passed to future generations, noting that current IVF screening already addresses most cases.
- Proponents like Ian Watts and Cheyenne Ziegler, who have undergone multiple IVF cycles for Charcot-Marie-Tooth disease, argue that editing offers a viable path to having children when screening yields too few healthy embryos.
- Columbia University researchers demonstrated high-accuracy base editing in human embryos in June 2026, though they noted the technology is not yet ready for clinical use due to inconsistent genomic changes.
Background
The debate over germline editing intensified after Chinese scientist He Jiankui was imprisoned in 2018 for creating the first gene-edited babies. Recent archive coverage highlights that while base editing shows promise in correcting specific mutations like PCSK9, safety concerns regarding chromosomal abnormalities and off-target effects persist. Origin Genomics, which previously operated under the name Manhattan Genomics, is now testing AI-assisted editors on donated embryos and stem cell lines, aiming to gather data to persuade regulators to lift bans.
How outlets are covering it
WIRED emphasizes the ethical argument that medicine should prevent avoidable suffering, citing Tie’s stance that editing is close to being safe. NPR highlights the emotional toll on families like the Ezras, who donated embryos to Origin, and notes concerns from bioethicists like Robin Lovell-Badge about 'false hope' and rushed progress. VCY.org frames the issue as a moral slippery slope toward eugenics, citing historical parallels to compulsory sterilization and warning that base editing enables enhancement, not just therapy. While WIRED and NPR focus on patient demand and technical progress, VCY.org and critics like Katie Hasson warn of a dystopian future of 'designer babies' and unregulated overseas clinics.
Why it matters
The push to legalize and fund human embryo editing challenges existing bioethical boundaries and U.S. federal restrictions. If Origin Genomics succeeds in proving safety, it could reshape reproductive medicine, offering solutions for rare genetic disorders but also raising profound questions about genetic enhancement, equity, and the long-term safety of heritable modifications.
What to watch
Origin Genomics expects to release significant safety and efficiency data in the coming months. The company is not currently using animal models but aims to build a case for lifting FDA bans. Meanwhile, Columbia researchers continue refining base editing tools, though they conclude the technology is not yet ready for clinical use due to variability in outcomes.
Want the full story? Read the original reporting
Read on WIRED